|
Abbreviation
|
Formula
|
Mass
|
Main Class
|
Sub Class
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C80H144N2O37
|
1724.944805
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C80H145NO38
|
1727.944471
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C84H151N3O33
|
1730.022994
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C84H151N3O33
|
1730.022994
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C84H151N3O33
|
1730.022994
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C84H151N3O33
|
1730.022994
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C84H153N3O33
|
1732.038644
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C84H153N3O33
|
1732.038644
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C84H153N3O33
|
1732.038644
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C84H153N3O33
|
1732.038644
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C80H143N3O37
|
1737.940054
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C80H143N3O37
|
1737.940054
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C80H143N3O37
|
1737.940054
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C80H143N3O37
|
1737.940054
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C80H144N2O38
|
1740.939720
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C84H150N4O33
|
1743.018243
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C84H152N4O33
|
1745.033893
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C82H148N2O37
|
1752.976105
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C80H143N3O38
|
1753.934969
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C82H149NO38
|
1755.975772
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C82H147N3O37
|
1765.971354
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C82H147N3O37
|
1765.971354
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C82H147N3O37
|
1765.971354
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C82H147N3O37
|
1765.971354
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C82H148N2O38
|
1768.971020
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C86H154N4O33
|
1771.049543
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C86H156N4O33
|
1773.065193
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C84H152N2O37
|
1781.007405
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C82H147N3O38
|
1781.966269
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C84H151NO38
|
1781.991422
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C84H153NO38
|
1784.007072
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C84H151N3O37
|
1794.002654
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C84H151N3O37
|
1794.002654
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C84H151N3O37
|
1794.002654
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C84H151N3O37
|
1794.002654
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C82H146N4O38
|
1794.961518
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C84H152N2O38
|
1797.002320
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C86H154N2O37
|
1807.023055
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C86H156N2O37
|
1809.038705
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C84H151N3O38
|
1809.997569
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C86H155NO38
|
1810.022722
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C86H157NO38
|
1812.038372
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C86H155N3O37
|
1822.033954
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C86H155N3O37
|
1822.033954
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C86H155N3O37
|
1822.033954
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C86H155N3O37
|
1822.033954
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C84H150N4O38
|
1822.992818
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C86H154N2O38
|
1823.017970
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C86H156N2O38
|
1825.033620
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C82H147NO43
|
1833.934697
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|